Molecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612.
Molecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612.
J Biol Chem. 2010 Mar 26;285(13):9813-9822. doi: 10.1074/jbc.M109.091496. Epub 2010 Jan 27.
CDKN1C is a cyclin-dependent kinase inhibitor and is a candidate tumor suppressor gene. We previously found that the CDKN1C protein represses E2F1-driven transcription in an apparent negative feedback loop. Herein, we explore the mechanism by which CDKN1C represses transcription. We find that adenoviral-mediated overexpression of CDKN1C leads to a dramatic reduction in phosphorylation of the RNA polymerase II (pol II) C-terminal domain (CTD). RNA interference studies demonstrate that this activity is not an artifact of CDKN1C overexpression, because endogenous CDKN1C mediates an inhibition of RNA pol II CTD phosphorylation in HeLa cells upon treatment with dexamethasone. Surprisingly, we find that CDKN1C-mediated repression of RNA pol II phosphorylation is E2F1-dependent, suggesting that E2F1 may direct CDKN1C to chromatin. Chromatin immunoprecipitation assays demonstrate that CDKN1C is associated with E2F1-regulated promoters in vivo and that this association can dramatically reduce the level of RNA pol II CTD phosphorylation at both Ser-2 and Ser-5 of the C-terminal domain repeat. In addition, we show that CDKN1C interacts with both CDK7 and CDK9 (putative RNA pol II CTD kinases) and that CDKN1C blocks their ability to phosphorylate a glutathione S-transferase-CTD fusion protein in vitro. E2F1 and CDKN1C are found to form stable complexes both in vivo and in vitro. Molecular studies demonstrate that the E2F1-CDKN1C interaction is mediated by two E2F domains. A central E2F1 domain interacts directly with CDKN1C, whereas a C-terminal E2F1 domain interacts with CDKN1C via interaction with Rb. The results presented in this report highlight a novel mechanism of tumor suppression by CDKN1C.
CDKN1C 是一种细胞周期蛋白依赖性激酶抑制剂,也是候选肿瘤抑制基因。我们之前发现 CDKN1C 蛋白在一个明显的负反馈环中抑制 E2F1 驱动的转录。在此,我们探讨了 CDKN1C 抑制转录的机制。我们发现腺病毒介导的 CDKN1C 过表达导致 RNA 聚合酶 II(pol II)C 端结构域(CTD)的磷酸化显著减少。RNA 干扰研究表明,这种活性不是 CDKN1C 过表达的假象,因为内源性 CDKN1C 在 HeLa 细胞中用地塞米松处理时介导 RNA pol II CTD 磷酸化的抑制。令人惊讶的是,我们发现 CDKN1C 介导的 RNA pol II 磷酸化抑制是 E2F1 依赖性的,表明 E2F1 可能将 CDKN1C 引导到染色质上。染色质免疫沉淀测定表明,CDKN1C 在体内与 E2F1 调节的启动子相关联,并且这种关联可以显著降低 CTD 重复的 Ser-2 和 Ser-5 上的 RNA pol II CTD 磷酸化水平。此外,我们表明 CDKN1C 与 CDK7 和 CDK9(假定的 RNA pol II CTD 激酶)相互作用,并且 CDKN1C 阻止它们在体外磷酸化谷胱甘肽 S-转移酶-CTD 融合蛋白的能力。E2F1 和 CDKN1C 被发现既在体内也在体外形成稳定的复合物。分子研究表明,E2F1-CDKN1C 相互作用由两个 E2F 结构域介导。中央 E2F1 结构域与 CDKN1C 直接相互作用,而 C 端 E2F1 结构域通过与 Rb 的相互作用与 CDKN1C 相互作用。本报告中提出的结果强调了 CDKN1C 抑制肿瘤的一种新机制。